These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38577255)

  • 1. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities.
    Fernandes EAF; van Oudtshoorn J; Tam A; González LCA; Aurela EG; Potthast H; Mettke K; Kuribayashi R; Shimojo K; Kasuga M; Morales L; Rodríguez Z; Jones B; Ahn C; Yun E; Kim SH; Rodrigues C; Tiong T; Crane C; Walther C; Roost MS; Chen TL; Hsu LF; Braddy AC; García-Arieta A; Abalos I; Divinsky M; Alsuwyeh A; Alzenaidy B; Alharf A
    J Pharm Pharm Sci; 2024; 27():12398. PubMed ID: 38577255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities.
    Roost MS; Potthast H; Walther C; García-Arieta A; Abalos I; Agostinho Freitas Fernandes E; Mendes Lima Santos G; Rodríguez Martínez Z; Tam A; Rodrigues C; Gutierrez Triana DA; Guzmán Aurela E; Rodríguez Rodríguez N; Aeh Park S; Kim J; Kariv R; Divinsky M; Jones B; Kuribayashi R; Myoenzono A; Kasuga M; Van Oudtshoorn J; Chi JF; Hung WY; Hsu LF; Crane C; Jarman T; Braddy A
    J Pharm Pharm Sci; 2021; 24():548-562. PubMed ID: 34706215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme.
    Garcia Arieta A; Simon C; Tam A; Mendes Lima Santos G; Freitas Fernandes EA; Rodríguez Martínez Z; Rodrigues C; Park SA; Kim J; Kim K; Kuribayashi R; Myoenzono A; Shimojo K; Walther C; Roost MS; Hung WY; Hsu LF; Crane C; Braddy AC; Van Oudtshoorn J; Gutierrez Triana DA; Guzmán Aurela E; Jones B; Potthast H; Abalos I
    J Pharm Pharm Sci; 2021; 24():113-126. PubMed ID: 33734975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme.
    Tam A; Garcia-Arieta A; Abalos I; Agostinho Freitas Fernandes E; Mendes Lima Santos G; Rodriguez Martinez Z; Divinsky M; Kariv R; Potthast H; Braddy AC; Rodrigues C; Guzman Aurela E; Carolina Arevalo Gonzalez L; Gutierres Triana D; Jones B; Ahn C; Kim H; Kim SH; Kuribayashi R; Myoenzono A; Shimojo K; Van Oudtshoorn J; Bigler C; Meincke R; Roost MS; Walther C; Hsu LF; Crane C; Jarman T
    J Pharm Pharm Sci; 2022; 25():323-339. PubMed ID: 36251699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global harmonization of immediate-release solid oral drug product bioequivalence recommendations and the impact on generic drug development.
    Kotsybar J; Hakeem S; Zhang L; Jiang W
    Clin Transl Sci; 2023 Dec; 16(12):2756-2764. PubMed ID: 37904315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Requirements for Additional Strength Biowaivers for Immediate Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities.
    Crane C; Santos GML; Fernandes EAF; Simon C; Tam A; Triana DG; Potthast H; Kuribayashi R; Okada Y; Myoenzono A; Calderon IO; Rodriguez Z; Jones B; Park SA; Eum SY; Rodrigues C; Van Oudsthoorn J; Nolting A; Walther C; Roost MS; Hung WY; Braddy AC; Garcia-Arieta A
    J Pharm Pharm Sci; 2019; 22(1):486-500. PubMed ID: 33760728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme.
    Garcia Arieta A; Simon C; Lima Santos GM; Calderón Lojero IO; Rodríguez Martínez Z; Rodrigues C; Park SA; Kim JM; Kuribayashi R; Okada Y; Nolting A; Pfäffli C; Hung WY; Crane C; Braddy AC; Van Oudtshoorn J; Gutierrez Triana D; Clarke M
    J Pharm Pharm Sci; 2019; 22(1):28-36. PubMed ID: 30599818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open forum conference on the ICH M13A bioequivalence guideline.
    Blume H; Wedemeyer S; Seidlitz A; Beuerle G; Klein S; Bilensoy E
    Eur J Pharm Sci; 2024 May; 196():106741. PubMed ID: 38452875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
    Kaur P; Chaurasia CS; Davit BM; Conner DP
    J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
    Davit B; Braddy AC; Conner DP; Yu LX
    AAPS J; 2013 Oct; 15(4):974-90. PubMed ID: 23821352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Harmonization of Comparator Products for Bioequivalence Studies.
    Gwaza L; Gordon J; Leufkens H; Stahl M; García-Arieta A
    AAPS J; 2017 May; 19(3):603-606. PubMed ID: 28265983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
    Kuribayashi R; Yamaguchi T; Takagi K
    Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action.
    Verbeeck RK; Musuamba FT
    J Pharm Pharm Sci; 2012; 15(3):376-88. PubMed ID: 23148877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International harmonization of bioequivalence studies and issues shared in common.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.
    Li X; Liu L; Deng Y; Li Y; Zhang P; Wang Y; Xu B; Feng J; Huang L
    Clin Pharmacol Drug Dev; 2021 May; 10(5):535-541. PubMed ID: 32770665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.